Newsroom

January 2021

• Ad hoc release Jan 29, 2021

  Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis

   Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS1CHMP opinion is…
• Press release Jan 29, 2021

  Novartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccine

  First of multiple agreements being explored by Novartis to leverage manufacturing capacity and capabilities to address pandemic, supporting global supply of COVID-19 vaccine Initial agreement signed…
• Press release Jan 29, 2021

  Novartis renews WHO medicine donation pledge with aim of ending leprosy

   Novartis leprosy medicine donation program with WHO extended to 2025 Program has already treated over 7 million patients since 2000 New evidence from contact tracing and preventive treatment…
• Featured News Jan 26, 2021

  Novartis ranks second in 2021 Access to Medicine Index

  Novartis maintained its position in the 2021 Access to Medicine Index, leading in its approach to product delivery, while performing strongly across all other areas of the Index.

• Ad hoc release Jan 26, 2021

  Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.

  Full year net sales from continuing operations¹ up 3% (cc², +3% USD): Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Zolgensma (reaching USD 0.9 billion), Cosentyx (+13% cc…
• Ad hoc release Jan 26, 2021

  Novartis hat 2020 Umsatz und Margen gesteigert und die nächste Welle von Medikamenten weiter vorangetrieben

  Der Nettoumsatz der fortzuführenden Geschäftsbereiche¹ stieg im Geschäftsjahr um 3% (kWk², +3% USD): Die Geschäftseinheit Pharmaceuticals wuchs um 5% (kWk), wozu vor allem Entresto (+44%…
• Ad hoc release Jan 26, 2021

  En 2020, Novartis a enregistré une croissance de son chiffre d’affaires et de sa marge; il a continué de faire progresser sa prochaine vague de médicaments

  Chiffre d’affaires net des activités poursuivies1 en hausse de 3% (tcc2, +3% USD): Pharmaceuticals: cette unité opérationnelle a progressé de 5% (tcc), soutenue par Entresto (+44%…
• 
  Story Jan 21, 2021 Patient Perspectives

  Digital innovation looks set to dominate the 2021 healthcare agenda

  Two Novartis leaders share their perspectives on digital health in 2020 – and the key trends to watch out for over the next 12 months.

• Press release Jan 19, 2021

  Novartis and GSK announce collaboration to support scientific research into genetic diversity in Africa

  Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients Combined…
• Press release Jan 14, 2021

  Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)

  Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines1 Currently…
• In The News Jan 13, 2021

  Pandemic has been a reset for pharma’s reputation

• Press release Jan 11, 2021

  Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene

  Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growthNovartis secures development and…